Contribution of TNF-α to the development of retinal neurodegenerative disorders

European Cytokine Network

Volumn 24, Issue 1, 2013, Pages 27-36

  Al Gayyar, M M ^a   Elsherbiny, N M ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b DELTA UNIVERSITY FOR SCIENCE AND TECHNOLOGY   (Egypt)

Author keywords

Age related macular degeneration; Glaucoma; Ischemic retinopathy; Neurodegenerative disorders; Retinitis pigmentosa; TNF

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ENDOTHELIN; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID; PROTEIN KINASE C; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CROHN DISEASE; CYTOTOXICITY; DAILY LIFE ACTIVITY; GLAUCOMA; HUMAN; IMMUNE RESPONSE; MACROPHAGE; NERVE DEGENERATION; NONHUMAN; PIGMENT EPITHELIUM; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; RETINOPATHY; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SUBRETINAL NEOVASCULARIZATION; ULCERATIVE COLITIS; VISUAL IMPAIRMENT;

AGE-RELATED MACULAR DEGENERATION; GLAUCOMA; ISCHEMIC RETINOPATHY; NEURODEGENERATIVE DISORDERS; RETINITIS PIGMENTOSA; TNF-Α;

ANIMALS; HUMANS; NECROSIS; NEURODEGENERATIVE DISEASES; PERMEABILITY; RETINAL DISEASES; RETINAL VESSELS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878105372     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2013.0334     Document Type: Article

References (83)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72: 3666-3670
2. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5: 392-399
3. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45-65
4. Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 2010; 22: 977-983
5. Figiel I. Pro-inflammatory cytokine TNF-alpha as a neuroprotective agent in the brain. Acta Neurobiol Exp (Wars) 2008; 68: 526-534
6. Shen HM, Pervaiz S. TNF receptor superfamily-induced cell death: redox-dependent execution. FASEB J 2006; 20: 1589-1598
7. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res, 173: 409-421
8. Mirshahi A, Hoehn R, Lorenz K, Kramann C, Baatz H (2012) Antitumor necrosis factor alpha for retinal diseases: current knowledge and future concepts. J Ophthalmic Vis Res 2008; 7: 39-44
9. Vauloup C, Krzysiek R, Greangeot-Keros L, et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006; 17: 290-293
10. Popa C, Barrera P, Joosten LA, et al. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents. Eur Cytokine Netw 2009; 20: 88-93
11. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-1206
12. Akassoglou K, Douni E, Bauer J, Lassmann H, Kollias G, Probert L. Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice. Proc Natl Acad Sci U S A 2003; 100: 709-714
13. Kraft AD, McPherson CA, Harry GJ. Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. Neurotoxicology 2009; 30: 785-793
14. Venters HD, Dantzer R, Kelley KW. A new concept in neurodegeneration: TNFalpha is a silencer of survival signals. Trends Neurosci 2000; 23: 175-180
15. Tezel G, Yang X. Caspase-independent component of retinal ganglion cell death, in vitro. Invest Ophthalmol Vis Sci 2004; 45: 4049-4059
16. Pickering M, Cumiskey D, O'Connor JJ. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 2005; 90: 663-670
17. Al-Gayyar MM, Abdelsaid MA, Matragoon S, Pillai BA, El- Remessy AB. Thioredoxin interacting protein is a novel mediator of retinal inflammation and neurotoxicity. Br J Pharmacol 2011; 164: 170-180
18. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol 2000; 118: 666-673
19. Desai D, He S, Yorio T, Krishnamoorthy RR, Prasanna G. Hypoxia augments TNF-alpha-mediated endothelin-1 release and cell proliferation in human optic nerve head astrocytes. Biochem Biophys Res Commun 2004; 318: 642-648
20. Zhang H, Park Y, Wu J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009; 116: 219-230
21. Lejeune FJ. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 2002; 110: 433-435
22. Gao X, Belmadani S, Picchi A, et al. Tumor necrosis factoralpha induces endothelial dysfunction in Lepr(db) mice. Circulation 2007; 115: 245-254
23. Picchi A, Gao X, Belmadani S, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 2006; 99: 69-77
24. Aoki N, Siegfried M, Lefer AM. Anti-EDRF effect of tumor necrosis factor in isolated, perfused cat carotid arteries. Am J Physiol 1989; 256: H1509-H1512
25. Ahmad M, Zhang Y, Papharalambus C, Alexander RW. Role of isoprenylcysteine carboxyl methyltransferase in tumor necrosis factor-alpha stimulation of expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 759-764
26. dela Paz NG, Simeonidis S, Leo C, Rose DW, Collins T. Regulation of NF-kappaB-dependent gene expression by the POU domain transcription factor Oct-1. J Biol Chem 2007; 282: 8424-8434
27. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factorkappaB: its role in health and disease. J Mol Med (Berl) 2004; 82: 434-448
28. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005; 434: 1138-1143
29. Bull ND, Martin KR. Concise review: toward stem cell-based therapies for retinal neurodegenerative diseases. Stem Cells 2011; 29: 1170-1175
30. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267
31. Ozawa Y, Sasaki M, Takahashi N, Kamoshita M, Miyake S, Tsubota K. Neuroprotective effects of lutein in the retina. Curr Pharm Des 2012; 18: 51-56
32. Mordes D, Luo X, Kar A, et al. Pre-mRNA splicing and retinitis pigmentosa. Mol Vis 2006; 12: 1259-1271
33. Cheung W, Guo L, Cordeiro MF. Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci 2008; 85: 406-416
34. Bazan NG. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J Lipid Res 2009; 50 Suppl: S400-S405
35. Sawada H, Fukuchi T, Tanaka T, Abe H. Tumor necrosis factoralpha concentrations in the aqueous humor of patients with glaucoma. Invest Ophthalmol Vis Sci 2010; 51: 903-906
36. Huang P, Qi Y, Xu YS, et al. Serum cytokine alteration is associated with optic neuropathy in human primary open angle glaucoma. J Glaucoma 2010; 19: 324-330
37. Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 2001; 42: 1787-1794
38. Kitaoka Y, Kwong JM, Ross-Cisneros FN, et al. TNF-alpha-induced optic nerve degeneration and nuclear factor-kappaB p65. Invest Ophthalmol Vis Sci 2006; 47: 1448-1457
39. Al-Gayyar MM, Matragoon S, Pillai BA, Ali TK, Abdelsaid MA, El-Remessy AB. Epicatechin blocks pro-nerve growth factor (proNGF)-mediated retinal neurodegeneration via inhibition of p75 neurotrophin receptor expression in a rat model of diabetes [corrected]. Diabetologia 2011; 54: 669-680
40. Ali TK, Al-Gayyar MM, Matragoon S, et al. Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia 2011; 54: 657-668
41. Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 2006; 26: 12633-12641
42. Hong S, Kim CY, Lee JE, Seong GJ. Agmatine protects cultured retinal ganglion cells from tumor necrosis factor-alpha-induced apoptosis. Life Sci 2009; 84: 28-32
43. Tezel G, Wax MB. Increased production of tumor necrosis factoralpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci 2000; 20: 8693-8700
44. Laengle UW, Markstein R, Pralet D, Seewald W, Roman D. Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF-alpha release in vitro from activated rat mast cells. Exp Eye Res 2006; 83: 1335-1339
45. Laengle UW, Trendelenburg AU, Markstein R, Nogues V, Provencher-Bollinger A, Roman D. GLC756 decreases TNF-alpha via an alpha2 and beta2 adrenoceptor related mechanism. Exp Eye Res 2006; 83: 1246-1251
46. Roh M, Zhang Y, Murakami Y, et al. Etanercept, a Widely Used Inhibitor of Tumor Necrosis Factor-alpha (TNF- alpha), Prevents Retinal Ganglion Cell Loss in a Rat Model of Glaucoma. PLoS One 2012; 7: e40065
47. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006; 45: 982-989
48. Koike A, Handa T, Zako M. Trabeculotomy in a Behcet's Disease Patient OneWeek after Infliximab Administration. Case Report Ophthalmol 2012; 3: 151-155
49. Nishida T, Shibuya E, Asukata Y, et al. Clinical Course before and after Cataract and Glaucoma Surgery under Systemic Infliximab Therapy in Patients with Behcet's Disease. Case Report Ophthalmol 2011; 2: 189-192
50. Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol 2007; 125: 1221-124
51. Shi X, Semkova I, Muther PS, Dell S, Kociok N, Joussen AM. Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp Eye Res 2006; 83: 1325-3324
52. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 2004; 23: 91-147
53. Husain S, Liou GI, Crosson CE. Opioid receptor activation: suppression of ischemia/reperfusion-induced production of TNF-alpha in the retina. Invest Ophthalmol Vis Sci 2011; 52: 2577-2583
54. Berger S, Savitz SI, Nijhawan S, et al. Deleterious role of TNFalpha in retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2008; 49: 3605-3610
55. Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, Castro- Villegas Mdel C, Gallardo-Galera JM, Collantes-Estevez E. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 2004; 20: 155-157
56. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 2006; 20: 1366-1369
57. Saxena S, Khanna VK, Pant AB, Meyer CH, Singh VK. Elevated tumor necrosis factor in serum is associated with increased retinal ischemia in proliferative eales' disease. Pathobiology 2011; 78: 261-265
58. Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC. Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia 1999; 28: 114-127
59. Martin-Villalba A, Hahne M, Kleber S, et al. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 2001; 8: 679-686
60. Sugano M, Hata T, Tsuchida K, et al. Local delivery of soluble TNF-alpha receptor 1 gene reduces infarct size following ischemia/reperfusion injury in rats. Mol Cell Biochem 2004; 266: 127-132
61. Fuchs C, Forster V, Balse E, Sahel JA, Picaud S, Tessier LH. Retinalcell- conditioned medium prevents TNF-alpha-induced apoptosis of purified ganglion cells. Invest Ophthalmol Vis Sci 2005; 46: 2983-2991
62. Abcouwer SF, Lin CM, Wolpert EB, et al. Effects of ischemic preconditioning and bevacizumab on apoptosis and vascular permeability following retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2010; 51: 5920-5933
63. Khandhadia S, Cherry J, Lotery AJ. Age-related macular degeneration. Adv Exp Med Biol 2012; 724: 15-36
64. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Agerelated macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48: 257-293
65. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 2005; 85: 845-881
66. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006; 58: 353-363
67. Swaroop A, Chew EY, Rickman CB, Abecasis GR. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet 2009; 10: 19-43
68. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol 2009; 147: 825-830, 830 e821
69. Jin M, He S, Worpel V, Ryan SJ, Hinton DR. Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-alpha. Invest Ophthalmol Vis Sci 2000; 41: 4324-4332
70. Yang P, McKay BS, Allen JB, Jaffe GJ. Effect of NF-kappa B inhibition on TNF-alpha-induced apoptosis in human RPE cells. Invest Ophthalmol Vis Sci 2004; 45: 2438-2446
71. Nagineni CN, Kommineni VK, William A, Detrick B, Hooks JJ. Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J Cell Physiol 2012; 227: 116-126
72. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007; 27: 399-413
73. Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol 2005; 139: 537-540
74. Regatieri CV, Dreyfuss JL, Melo GB, Lavinsky D, Farah ME, Nader HB. Dual role of intravitreous infliximab in experimental choroidal neovascularization: effect on the expression of sulfated glycosaminoglycans. Invest Ophthalmol Vis Sci 2009; 50: 5487-5494
75. Lichtlen P, Lam TT, Nork TM, Streit T, Urech DM. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest Ophthalmol Vis Sci 2010; 51: 4738-4745
76. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis 2006; 1: 40
77. Chizzolini M, Galan A, Milan E, Sebastiani A, Costagliola C, Parmeggiani F. Good epidemiologic practice in retinitis pigmentosa: from phenotyping to biobanking. Curr Genomics 2011; 12: 260-266
78. Shintani K, Shechtman DL, Gurwood AS. Review and update: current treatment trends for patients with retinitis pigmentosa. Optometry 2009; 80: 384-401
79. Haim M, Rosenberg T. Retinitis pigmentosa and allied disorders in Denmark. IV. Ophthalmic features in systemic and non-systemic cases. Acta Ophthalmol (Copenh) 1993; 71: 597-605
80. Zeiss CJ, Johnson EA. Proliferation of microglia, but not photoreceptors, in the outer nuclear layer of the rd-1 mouse. Invest Ophthalmol Vis Sci 2004; 45: 971-976
81. Zeng HY, Zhu XA, Zhang C, Yang LP, Wu LM, Tso MO. Identification of sequential events and factors associated with microglial activation, migration, and cytotoxicity in retinal degeneration in rd mice. Invest Ophthalmol Vis Sci 2005; 46: 2992-2999
82. Zeng HY, Tso MO, Lai S, Lai H. Activation of nuclear factorkappaB during retinal degeneration in rd mice. Mol Vis 2008; 14: 1075-1080
83. Kanan Y, Centola M, Bart F, Al-Ubaidi MR. Analysis of genes differentially expressed during retinal degeneration in three mouse models. Adv Exp Med Biol 2010; 664: 3-13.